Literature DB >> 20967835

Treatment of pediatric pulmonary hypertension with simvastatin: an observational study.

Wilson T King1, Ronald W Day.   

Abstract

BACKGROUND: Animal studies and an adult human case series suggest that statins may have a role in the treatment of pulmonary hypertension. We reviewed the results of empirical therapy for children at Primary Children's Medical Center to determine whether simvastatin had a favorable effect on non-invasive estimates of pulmonary arterial pressure.
MATERIALS AND METHODS: The medical records of children with pulmonary hypertension who were treated with simvastatin were reviewed. Mean measurements of the gradient of tricuspid valve regurgitation before and after treatment were compared by a paired t-test. A favorable response to simvastatin was defined as a 20% decrease in the average measurement of the gradient of tricuspid valve regurgitation or a 20% decrease in right ventricular anterior wall thickness when tricuspid valve regurgitation resolved during treatment. Potential factors associated with a favorable response to simvastatin were identified with a Fisher exact test.
RESULTS: Twelve children, 4-15 years of age, had adequate Doppler velocity waveforms to reliably measure gradients of tricuspid valve regurgitation during a period of 1 year before treatment. Eleven patients had gradients of tricuspid valve regurgitation that could be measured during a period of 1 year after treatment. Patients were treated with simvastatin 0.09-0.28 mg/kg/day. Collectively, there was no difference between the average measurements of the gradient of tricuspid valve regurgitation before and after treatment (66 ± 21 mmHg vs. 63 ± 28 mmHg). Three of the five patients with clinical findings consistent with alveolar hypoxia and none of the seven patients without clinical findings consistent with alveolar hypoxia had a favorable response to treatment with simvastatin (P = 0.05).
CONCLUSION: Simvastatin may decrease pulmonary arterial pressure in a subset of patients with pulmonary hypertension.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Keywords:  alveolar hypoxia; pulmonary arterial hypertension; simvastatin

Mesh:

Substances:

Year:  2010        PMID: 20967835     DOI: 10.1002/ppul.21361

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases.

Authors:  Ming-Zhou Zhang; De-Hui Qian; Jian-Cheng Xu; Wei Yao; Ye Fan; Chang-Zheng Wang
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.

Authors:  Steven M Kawut; Emilia Bagiella; David J Lederer; Daichi Shimbo; Evelyn M Horn; Kari E Roberts; Nicholas S Hill; R Graham Barr; Erika B Rosenzweig; Wendy Post; Russell P Tracy; Harold I Palevsky; Paul M Hassoun; Reda E Girgis
Journal:  Circulation       Date:  2011-05-18       Impact factor: 29.690

3.  Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lin Wang; Moying Qu; Yao Chen; Yaxiong Zhou; Zhi Wan
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

Review 4.  Are statins beneficial for the treatment of pulmonary hypertension?

Authors:  Lei Wang; Ting Yang; Chen Wang
Journal:  Chronic Dis Transl Med       Date:  2017-12-11

Review 5.  Oxidative Stress and Its Implications in the Right Ventricular Remodeling Secondary to Pulmonary Hypertension.

Authors:  Matthew Mikhael; Christian Makar; Amir Wissa; Trixie Le; Mansoureh Eghbali; Soban Umar
Journal:  Front Physiol       Date:  2019-09-24       Impact factor: 4.566

6.  Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Fangying Chen; Mei Yang; Chun Wan; Lin Liu; Lei Chen
Journal:  Ann Transl Med       Date:  2019-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.